Comorbidities
GLP-1s and Fatty Liver Disease
The commonest liver disease in the world has no approved drug for most of the people who have it, and a large share of them are sitting in front of a prescription that treats the thing causing it.
This is the diagnosis most people on these drugs have and have not been told about, usually because it was mentioned once as “a bit of fat on the liver” during an ultrasound for something else.
What it is, and why the name changed
Metabolic dysfunction-associated steatotic liver disease — MASLD — is fat accumulation in the liver driven by metabolic factors. It is now the most common chronic liver disease worldwide, and it tracks closely with weight, insulin resistance and type 2 diabetes.
It was called NAFLD until recently. The rename matters slightly: “non-alcoholic fatty liver disease” defined a condition by what it was not, which is unhelpful, and the new terminology names the actual driver.
The distinction worth understanding is between MASLD and MASH:
| What it is | Why it matters | |
|---|---|---|
| MASLD | Fat in the liver | Very common, often does not progress |
| MASH | Fat plus inflammation and cell injury | The form that scars |
| Fibrosis | Scarring, staged F0–F4 | The thing that predicts outcomes |
Fibrosis stage is what predicts liver outcomes, not how much fat is there. Someone with a lot of fat and no scarring is in a better position than someone with less fat and stage 3 fibrosis.
What the trials show
The mechanism was known long before these drugs: 7–10% weight loss improves steatohepatitis, and losses above 10% improve it more. A well-known 2015 study of lifestyle-induced weight loss found resolution of steatohepatitis in a large proportion of those reaching 10%.
Then the drug trials arrived. A randomised placebo-controlled trial of semaglutide in non-alcoholic steatohepatitis, published in the NEJM in 2021, found significantly higher rates of resolution of steatohepatitis than placebo. A trial of tirzepatide in MASH with fibrosis, published in 2024, reported similar direction.
Two honest caveats. Resolution of inflammation is more consistently demonstrated than regression of fibrosis, which is slower and harder to show. And these are biopsy endpoints in selected trial populations — worth reading with the checks in how to read a GLP-1 study rather than as a settled cure.
The number to ask for
Most people with fatty liver never find out whether they have the version that matters, because the useful test is not ordered.
Ask for a FIB-4 score. It is a calculation, not a new blood test — age, ALT, AST and platelet count, all of which you have probably already had. It stratifies you into low, indeterminate or high risk of advanced fibrosis.
- Low FIB-4: genuinely reassuring. Recheck periodically.
- Indeterminate or high: warrants further assessment, usually transient elastography or referral.
This is the single highest-value thing in this article, it costs nothing, and it is the reason reading your own labs argues for asking about the numbers you already have rather than ordering more.
What to make of your liver enzymes
A mildly raised ALT is extremely common in this population and by itself is weak information. It commonly improves as weight falls — often within the first months.
What is more informative:
- A falling platelet count over years, which can indicate portal hypertension and is easy to overlook because each individual result looks normal.
- AST higher than ALT, which in this context raises the question of more advanced disease — or of alcohol, which is worth being straight with yourself about.
- A rising FIB-4 over time, which is the trend that changes management.
Alcohol, briefly and directly
Metabolic and alcohol-related liver injury are additive, and this is a place where the honest conversation is more useful than the polite one. If you have MASLD with any fibrosis, alcohol is not a neutral input.
There is also a specific reason it comes up on this drug: people frequently report that they want less of it, and that a smaller amount goes further — drinking alcohol on a GLP-1 covers both, including the research on reduced craving.
What this changes practically
If you have MASLD or MASH and are prescribed a GLP-1 for weight or diabetes, you are already treating it. That is worth knowing, partly because it reframes the medication and partly because it strengthens a coverage appeal — a documented liver diagnosis is a clinical indication rather than a cosmetic request, which is the argument made at length in what a GLP-1 actually costs.
Get a baseline FIB-4 before or early in treatment, so a later value means something.
Protect muscle, because sarcopenia and liver fibrosis travel together and losing weight badly is worse for the liver than losing it slowly — muscle is the whole game.
Expect the numbers to move slowly. Enzymes respond over 3–6 months; fibrosis, where it responds, responds over years. A liver panel at week six tells you very little.
And if you have established cirrhosis, this is specialist territory rather than an article’s, and the medication decisions there are made with a hepatologist involved.
Questions I get about this month
- Does Ozempic help fatty liver disease?
- The evidence is good and getting better. A randomised trial of semaglutide in non-alcoholic steatohepatitis published in 2021 found significantly higher rates of resolution of steatohepatitis than placebo, and subsequent trials of both semaglutide and tirzepatide in metabolic dysfunction-associated steatohepatitis have reported similar direction. Much of the benefit comes through weight loss itself, since a 7–10% reduction is the best-established intervention for this condition regardless of how it is achieved.
- What is the difference between MASLD, NAFLD and MASH?
- Mostly naming. NAFLD, non-alcoholic fatty liver disease, was renamed MASLD — metabolic dysfunction-associated steatotic liver disease — to describe what actually drives it rather than what it is not. MASH is the inflammatory form, previously NASH, where fat is accompanied by inflammation and liver cell injury. MASLD is common and often harmless; MASH is the version that progresses to fibrosis and cirrhosis, and telling them apart requires more than an ultrasound.
- My ALT is slightly high. Should I worry?
- Usually not on its own, and it should not be ignored either. Mildly raised transaminases are extremely common in people with excess weight, and they typically improve as weight falls — often within months of starting treatment. The number that matters more is a fibrosis estimate. Ask for a FIB-4 score, which is calculated from age, ALT, AST and platelet count, all of which you have probably already had drawn. A low FIB-4 is genuinely reassuring; an indeterminate or high one warrants further assessment.
- Do I need a liver scan before starting a GLP-1?
- Not routinely. What is worth doing is a baseline liver panel and a FIB-4 calculation, because they cost nothing extra and give you something to compare against later. Specialised imaging such as transient elastography is for people whose FIB-4 is indeterminate or high, or who have other risk factors — type 2 diabetes, a family history of cirrhosis, or significant alcohol intake. That is a decision for a clinician rather than a routine step for everyone.
Sources
- 01Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM, 2021.
- 02Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. NEJM, 2024.
- 03Vilar-Gomez E et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015.
- 04Sterling RK et al. Development of a simple noninvasive index to predict significant fibrosis (FIB-4). Hepatology, 2006.
- 05Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023.
Elise Hall, MD
Board-certified internist in Los Angeles, twenty-one years in practice. She writes about GLP-1 medications and metabolic health for people who want the reasoning, not just the conclusion — and publishes her own year on one of these drugs alongside it.
Keep reading
Supplements
The Best Supplements for GLP-1 Hair Loss
The shedding starts two to four months after the loss speeds up, which is why almost nobody connects the two. Seven supplements ranked — and one of them interferes with the blood test that rules out a heart attack.
Supplements
Best Bone Health Supplements on a GLP-1
Bone is the tissue nobody thinks about until a wrist breaks. Rapid weight loss reduces bone mineral density, the effect is largest in exactly the people most likely to be prescribed these drugs, and none of it produces a symptom until it does.
Tools
The Best GLP-1 Apps, Ranked
I scored every tracker I could get my hands on against seven criteria that matter specifically on a GLP-1 — not generic calorie counting. Here is the ranking, the rubric behind it, and where my first choice falls short.